超越SGLT2:近端小管转运体作为慢性肾脏病的潜在药物靶点
本文综述了近端小管转运体作为慢性肾脏病治疗靶点的研究进展。近端小管负责重吸收大部分滤过的溶质和水,并分泌代谢废物和药物。SGLT2抑制剂已是CKD标准治疗,而NHE3抑制剂、尿酸转运体调节剂以及磷酸盐、氨基酸转运体抑制剂等新型药物展现出潜力,文章讨论了这些靶点的优势与挑战。
要点
- SGLT2抑制剂已作为CKD标准治疗,而NHE3间接抑制剂(乙酰唑胺)主要用于心衰或预防高山病。
- 促尿酸排泄药物已用于痛风患者,并可能预防肾脏病;磷酸盐和氨基酸转运体抑制剂是新型研发方向。
- 近端小管转运体与肾脏代谢和全身代谢相关,其调控可能影响肾脏病的发生、进展和后果。
核心结论
- 近端小管转运体是现有药物和新型策略的有吸引力的靶点,可用于减少肾脏病进展或减轻肾功能下降的后果。
研究设计与样本
- 本文为综述,检索范围未在原文中明确报告。
主要发现
- 肾脏每日产生约180升尿液,但仅约2升被排出,近端小管重吸收大部分滤过的溶质和水。
- SGLT2抑制剂已成功用于肾脏病、糖尿病或心衰患者,是CKD标准治疗的一部分。
- NHE3的间接抑制剂乙酰唑胺主要用于心衰患者或预防高山病,而直接抑制剂在临床前研究中显示可减少急性肾损伤或高血压的损害。
- 调节尿酸排泄的转运体调节剂已用于痛风患者,并讨论用于预防肾脏病。
- 研发中的新药靶向磷酸盐、氨基酸或毒素与药物排泄的转运体,可能对特定肾脏病相关状况有帮助。
临床怎么用
- SGLT2抑制剂应作为CKD和/或心衰患者的标准治疗组成部分。
- 乙酰唑胺作为NHE3间接抑制剂,可用于心衰患者或预防高山病。
- 促尿酸排泄药物可用于痛风患者,并可能具有预防肾脏病的潜力。
局限性
- 本文为综述,未报告原始研究的具体样本量、阈值或统计学数据。
- 新型药物(如NHE3直接抑制剂、磷酸盐和氨基酸转运体抑制剂)的临床获益尚需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The kidneys produce daily about 180 liters of urine but only about 2 liters are excreted. The proximal tubule plays an important role in reabsorbing the majority of filtered urine and many metabolites such as sugars, amino acids, salts or phosphate that are contained in this large volume. Reabsorption of these important metabolites is mediated by a diverse group of highly specialized transport proteins. Another group of transport proteins in the proximal tubule is responsible for the active secretion of metabolic waste products or toxins and drugs into urine. All these transporters have in common that they are directly linked to kidney metabolism and indirectly to whole-body metabolism and functions. In recent years, it has become evident that modulation of these transporters may influence the onset, progression and consequences of kidney disease. This review summarizes recent developments in this field and discusses some examples of drugs already in clinical use or in development. The examples include inhibitors of sugar transporters (SGLT2 inhibitors) that are successfully used in patients with kidney disease, diabetes or heart failure. Likewise, indirect inhibitors (acetazolamide) of an transporter absorbing sodium in exchange for protons (NHE3) are used mostly in patients with heart failure or for prevention of high altitude disease, while direct inhibitors show promise in preclinical studies to reduce damage in episodes of acute kidney disease or high blood pressure. Modulators of transporters mediating the excretion of urate have been used in patients with gout and are also discussed to prevent kidney disease. Novel drugs in development target transporters for phosphate, amino acids, or toxin and drug excretion and may be helpful for specific conditions associated with kidney disease. The advantages and challenges associated with these (novel) drugs targeting proximal tubule transport are discussed. ABSTRACT: The proximal tubule is responsible for reabsorbing about 60% of filtered solutes and water and is critical for the secretion of metabolic waste products, drugs and toxins. A large number of highly specialized ion channels and transport proteins belonging to the SLC and ABC transporter families are involved. Their activity is directly or indirectly linked to ATP consumption and requires large quantities of energy and oxygen supply. Moreover, the activity of these transporters is often coupled to the movement of Na+ ions thus influencing also salt and water balance, as well as transport and regulatory processes in downstream segments. Because of their relevance for systemic ion balance, for renal metabolism or for affecting regulatory processes, proximal tubule transporters are attractive targets for existing drug and for novel strategies to reduce kidney disease progression or to alleviate the consequences of decreased kidney function. In this review, the relevance of some major proximal tubule transport systems as drug targets in individuals with chronic kidney disease (CKD) is discussed. Inhibitors of the sodium-glucose cotransporter 2, SGLT2, are now part of standard therapy in patients with CKD and/or heart failure. Also, indirect inhibition of Na+/H+-exchangers by carbonic anhydrase inhibitors and uricosuric drugs have been used for decades. Inhibition of phosphate and amino acid transporters have recently been proposed as novel principles to remove excess phosphate or to protect the proximal tubule metabolically, respectively. In addition, organic cation and anion transporters involved in drug and toxin excretion may serve as targets of new drugs. The advantages and challenges associated with (novel) drugs targeting proximal tubule transport are discussed.
引用
- Wagner CA. Beyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease. Nephrol Dial Transplant. 2025. PMID: 39907544. doi:10.1093/ndt/gfae211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。